The use of neutralizing anti-VEGFβ and anti-IL-17 antibodies in mice with DKD generated a decrease in the inflammatory reaction and renal fibrosis, as well as in renal lipid deposits, predominantly triglycerides [72]. This evidence concerns the gene VEGFB and diabetic kidney disease.